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Cystic fibrosis (CF) is caused by mutations in the CF trans-
membrane conductance regulator (CFTR) that prevent its
proper folding and trafficking to the apicalmembrane of epithe-
lial cells. Absence of cAMP-mediated Cl secretion in CF air-
ways causes poorly hydrated airway surfaces in CF patients, and
this condition is exacerbated by excessive Na absorption. The
mechanistic link between missing CFTR and increased Na
absorption in airway epithelia has remained elusive, although
substantial evidence implicates hyperactivity of the epithelial
Na channel (ENaC). ENaC is known to be activated by selective
endoproteolysis of the extracellular domains of its- and-sub-
units, and it was recently reported that ENaC and CFTR physi-
cally associate in mammalian cells. We confirmed this interac-
tion in oocytes by co-immunoprecipitation and found that
ENaC associated with wild-type CFTR was protected from pro-
teolytic cleavage and stimulation of open probability. In con-
trast, F508 CFTR, the most common mutant protein in CF
patients, failed to protect ENaC from proteolytic cleavage and
stimulation. In normal airway epithelial cells, ENaC was con-
tained in the anti-CFTR immunoprecipitate. In CF airway epi-
thelial cultures, the proportion of full-length to total -ENaC
protein signal was consistently reduced compared with normal
cultures. Our results identify limiting proteolytic cleavage of
ENaC as a mechanism by which CFTR down-regulates Na
absorption.
Elevated epithelial Na absorption was first detected by in
vivo assays of nasal and bronchial epithelial potential difference
in cystic fibrosis (CF)2 patients (1), and it has been shown to
contribute to depletion of airway surface liquid (ASL) in well
differentiated cultures of CF airway epithelial cells (2).Most CF
mutations causing severe disease practically eliminate the func-
tional CF transmembrane conductance regulator (CFTR) at the
apical membrane (3). Thus, Na hyperabsorption has been
attributed to loss of negative regulation of the epithelial Na
channel (ENaC) that is normally exerted by CFTR in airway
epithelia (4). The negative influence of CFTRonENaChas been
reconstituted in multiple in vitro cell models (2, 5–13). However,
suchwork has been controversial (14) and has yet to reveal a clear
and compelling mechanistic basis for the down-regulation of
ENaC by CFTR. Furthermore, the coordinated stimulation of
CFTR and ENaC in sweat ductal epithelium indicates that the
functional relationship of CFTR and ENaC varies with the tissue-
specific physiologic roles of these ion channels (15).
In recent years, ENaC regulation has become much better
understood. In particular, selective endoproteolysis of small
segments of the large extracellular domains of - and -ENaCs
has been shown to increase ENaC open probability (16–19).
Berdiev et al. (20, 21) recently demonstrated a physical associ-
ation of CFTR and ENaC in HEK293T cells overexpressing
these two channels. In this work, we assessed this association in
primary airway epithelial cells and inXenopus oocytes and eval-
uated its impact on ENaC regulation by partial endoproteolysis.
We confirm that CFTR physically associates with ENaC and
report for the first time that CFTR markedly impedes ENaC
stimulation by suppressing proteolysis of its extracellular
domains.
EXPERIMENTAL PROCEDURES
Culture Conditions and Protein Expression—Primary human
airway epithelial (HAE) cultures were derived from human
bronchial tissue as described previously (22) following a proto-
col approved by the University of North Carolina Medical
School Institutional Review Board. Fully differentiated HAE
cultures were obtained by maintaining cells at an air-liquid
interface for 21 days. Xenopus laevis oocytes were harvested
and maintained as described previously (23). Animals were
maintained and studied under protocols approved by the Uni-
versity of North Carolina Institutional Animal Care and Use
Committee. For protein expression in oocytes, 0.3 ng of cRNAs
encoding rat ENaC -, -, and -subunits were utilized. Either
the- or -ENaC construct was double-taggedwithHAandV5
epitopes at the N and C termini, respectively. cRNAs of
matriptase (1 ng) and CFTR (1 or 2 ng) or MRP1 (multidrug
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resistance protein 1; 1 or 2 ng) were co-injected. Oocytes were
maintained for 24 h before theywere used for functional studies
or for preparation of lysates for Western blotting.
Western Blot Analysis and Immunoprecipitation—Cell ly-
sates from HAE cultures were obtained, and Western blotting
was performed as described (24). Lysates from oocytes were
prepared similarly as described by Garcia-Caballero et al. (23).
Proteins were separated by 7, 10, or 4–20% SDS-PAGE and
then transferred to nitrocellulose for immunoblot analysis.
N-terminally HA-tagged and C-terminally V5-tagged - and
-ENaCs were visualized with anti-HA mAb (Covance) and
anti-V5 mAb (Invitrogen), respectively. CFTR was detected
with mAb 596 recognizing an epitope in NBD2 of CFTR (25),
MRP1 was detected with mAb 42.4 (26), and actin was visual-
ized as the loading control with rabbit anti-actin antibody
(Stressgen) or anti-actin mAb (Millipore). Immunoprecipita-
tions of proteins from oocyte lysates were performed as
described previously (23), with the exception that all immuno-
precipitations were performed in
Nonidet P-40 buffer (1% Nonidet
P-40, 150 mM NaCl, 50 mM Tris, 1
mM EGTA, 4 g of leupeptin, 8
g/ml aprotinin, 200 g/ml Pefab-
loc, 484 g/ml benzamidine, and 14
g/ml E64, pH 7.4). For immuno-
precipitation of CFTR, rabbit anti-
CFTR polyclonal antibody 155 was
utilized (27), and for immunopre-
cipitation of N-terminally HA-
tagged -ENaC, we applied rabbit
anti-HA antibody (Abcam ab9110),
both followed by pulldown with
protein A-Agarose (Invitrogen).
Human -ENaC was detected with
the specific mAb UNC1 19.2.1 rec-
ognizing an N-terminal epitope of
this subunit (supplemental Fig. 1).
For detection of primary antibod-
ies, we applied IRDye 680-conju-
gated goat anti-mouse IgG
(Invitrogen) or IRDye 800-conju-
gate goat anti-rabbit IgG (Rock-
land Immunochemicals) using an
Odyssey infrared imaging system
(LI-COR Biosciences).
Functional Studies in Xenopus
Oocytes—24 h after injection, two-
electrode voltage clamping was
performed using a GeneClamp
amplifier (MDS Analytical Tech-
nologies) as described previously
(23). Currents were measured in
the presence and absence of 10 M
amiloride, with membrane voltage
clamped to 100 mV. Currents
were digitized and recorded using a
Digidata 1200 A/D converter (MDS
Analytical Technologies) and Axo-
Scope software. Trypsin (2 g/ml) was perfused for 5 min after
first measuring the basal amiloride-sensitive current (INa). To
assess whole cell ENaC open probability (Po), oocytes were
injectedwith cRNA for wild-type-ENaC, S518C-ENaC, and
wild-type -ENaC. Basal INa was measured, methanethiosul-
fonate ethyltrimethylammonium (MTSET; 1 mM) was applied
for 5 min, and INa was determined again. Whole cell Po was
estimated from the ratio of basal INa to MTSET-stimulated INa
(28).
RESULTS
CFTR and ENaC Associate in Oocytes—To test for associa-
tion of CFTR and ENaC in Xenopus oocytes, we performed
CFTR and ENaC immunoprecipitations from four experimen-
tal groups (uninjected, ENaC only, CFTR only, and CFTR 
ENaC) (Fig. 1A). The resulting immunoprecipitated proteins
were then probed for the presence of ENaC and CFTR. CFTR
was immunoprecipitated from oocytes injected with CFTR
FIGURE 1. CFTR interacts with ENaC and decreases ENaC-mediated INa. A, CFTR and ENaC associate with
each other when expressed in Xenopus oocytes. Oocytes were injected with rat -, -, and HA/V5-tagged
-ENaC cRNAs in the absence or presence of CFTR cRNA. CFTR was immunoprecipitated (IP) with rabbit anti-
CFTR antibody 155, and HA/V5-tagged -ENaC was immunoprecipitated with rabbit anti-HA antibody (Abcam
ab9110). Immunoprecipitated proteins were detected by Western blotting using anti-CFTR mAb 596 and
anti-HA mAb (Covance HA.11). B, CFTR coexpression decreases ENaC-mediated INa. Current was recorded from
oocytes injected with ENaC cRNAs (0.3 ng/each) alone or with CFTR cRNA (1–2 ng). Amiloride was removed for
30 s to measure basal INa. Trypsin (2 g/ml) was applied for 5 min, and INa was determined again (n  84 oocytes
in each group, from 14 separate batches of oocytes). a, trypsin-stimulated versus basal INa (p  0.001);
b, ENaC 
CFTR basal versus ENaC basal INa (p  0.01);
c, CFTR  ENaC trypsin-stimulated versus ENaC trypsin-stimulated
INa. Analysis of variance with Tukey’s test was performed. C, CFTR coexpression increases stimulation of ENaC
by trypsin. ENaC INa reported in B was analyzed as -fold trypsin stimulation. In oocytes expressing ENaC, INa was
increased by 5.16  0.35-fold. In oocytes coexpressing ENaC and CFTR, trypsin increased INa by 8.69  0.46-fold
(n  84 oocytes in each group, from 14 separate batches of oocytes). a, p  0.001 by unpaired t test. D, CFTR
coexpression decreases ENaC whole cell open probability (Po). Oocytes were injected with cRNA for wild-type
- and -ENaCs and S518C -ENaC (0.3 ng each) alone or the same ENaC subunit combination with CFTR (1 ng).
Amiloride was removed for 30 s to measure basal INa. MTSET (1 mM) was applied for 5 min, and INa was
determined again. Whole cell Po was calculated from the ratio of basal INa to MTSET-stimulated INa (n  44
oocytes in each group, from 14 separate batches of oocytes). a, p  0.001 by unpaired t test.
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cRNA as the typical B and C bands (Fig. 1A, first panel), indi-
cating that oocytes produce core-glycosylated and mature
CFTR protein, respectively (29). We immunoprecipitated and
detected -ENaC using an antibody against its N-terminal HA
tag. -ENaC proteins immunoprecipitated with anti-HA anti-
body contained an 80–85-kDa band representing full-length
-ENaC, as well as an 15-kDa band known to be produced by
cleavagemediated by endogenous proteases at or near the furin
site (Fig. 1A, second panel) (19, 30).
We next probed -ENaC immunoprecipitates with anti-
CFTR antibody (Fig. 1A, third panel). The CFTR B andC bands
were detected in proteins immunoprecipitated by anti-HA
antibody, confirming that CFTR associates with -ENaC. In the
anti-CFTR immunoprecipitate, anti-HA antibody detected the
80–85-kDa full-length -ENaC band, demonstrating associ-
ation of ENaC with CFTR (Fig. 1A, fourth panel). Compared
with the same experimental group (CFTR  ENaC) immuno-
precipitated with anti-ENaC antibody (Fig. 1A, second panel),
just a fraction of the total amount of the 80–85-kDa -ENaC
band was detected in the anti-CFTR immunoprecipitate. Sur-
prisingly, the15-kDa band representing anN-terminal cleav-
age fragment of -ENaC was not present in the anti-CFTR
immunoprecipitate, even when overexposed. It is well estab-
lished that this N-terminal15-kDa band represents the prod-
uct of cleavage near the furin site in -ENaC and that it remains
associated with the larger C-terminal fragment during protein
isolation (31). Furthermore, detection of the 15-kDaband in the
-ENaC immunoprecipitate (Fig. 1A, second panel) indicates
that it was generated by endogenous
proteases in the oocyte groups
expressing ENaC, either alone or
with CFTR. Therefore, the absence
of the N-terminal 15-kDa fragment
of -ENaC in the CFTR immuno-
precipitate suggests that the pool of
ENaC closely associated with CFTR
was shielded from endogenous
proteases.
CFTR Decreases ENaC-mediated
INa—Endoproteolysis of - and -
ENaCs has been shown to increase
ENaC open probability (16, 32), and
if CFTR shielded -ENaC from pro-
teolytic activation, INa should be
decreased in CFTR ENaC oocytes
compared with ENaC-only oocytes.
Indeed, INa was reduced in oocytes
coexpressing ENaC andCFTR com-
pared with ENaC alone (Fig. 1B).
Furthermore, exogenous trypsin
caused a proportionately larger
stimulation of INa in oocytes coex-
pressing CFTR (Fig. 1, B and C).
This reduction in basal INa and
increased -fold trypsin stimulation
indicate reduced proteolytic activa-
tion of ENaC on the surface of
oocytes expressing CFTR. Previous
work in oocytes showing decreased ENaC current in the pres-
ence of CFTR has been criticized as a recording artifact
potentially introduced by the large conductance mediated by
CFTR (14). However, the increased -fold stimulation of INa
by trypsin in CFTR-expressing oocytes cannot be explained
by such a technical artifact. In addition, we used an inde-
pendent method to estimate the effects of CFTR on ENaC
open probability (Fig. 1D). ENaC constitutedwith the-ENaC
mutant S518C is converted to a locked open state when the
sulfhydryl-reactive reagent MTSET enters the pore and
covalently reactswith the introduced cysteine (33).Weused the
ratio of basal INa to MTSET-stimulated INa to estimate ENaC
open probability in oocytes coexpressing ENaC and CFTR
compared with oocytes expressing ENaC alone (28). CFTR
coexpression reduced ENaC open probability, consistent with
biochemical evidence that CFTR reduced cleavage of a pool of
ENaC.
CFTR Diminishes Proteolysis of ENaC—As the extent of
ENaCcleavage by endogenous proteases is variable, we chose to
test the apparent ability of CFTR to limit ENaC proteolysis
under more defined conditions. Therefore, we coexpressed
exogenous matriptase, which is known to fully activate ENaC
by a proteolytic mechanism (34). In oocytes expressing ENaC
only, we observed a low basal INa that was markedly stimulated
by the addition of trypsin (Fig. 2A). As predicted, ENaC coex-
pressed withmatriptase produced a large basal INa that was not
increased further by exogenous trypsin (Fig. 2A). When CFTR
was also coexpressed, basal ENaC currents were not increased
FIGURE 2. Specific inhibition of ENaC proteolysis and INa by CFTR. A, ENaC was expressed in Xenopus oocytes
(as described for Fig. 1B) alone, with matriptase (Mtrp), and with both matriptase and CFTR. Basal INa was
increased by matriptase and not further stimulated by exogenous trypsin (2 g/ml). CFTR prevented stimula-
tion of basal INa and restored sensitivity to exogenous trypsin. B, CFTR prevents proteolytic cleavage of - and
-ENaCs by matriptase. Oocytes were injected with all three ENaC subunits, whereby either the - or -subunit
was tagged at the N and C termini with HA and V5 epitopes, respectively. Similar experiments were performed
with coexpression of matriptase and CFTR or MRP1. Oocyte lysates were analyzed by Western blotting using
anti-V5 mAb to detect ENaC, mAb 596 to detect CFTR, and mAb 42.4 to visualize expression of MRP1. As a
control for loading of equal amounts of proteins, actin was detected with anti-actin mAb. C, experiments were
similar to those described for A except that CFTR was replaced by MRP1. Matriptase coexpression was associ-
ated with large basal INa that was unaffected by trypsin, and coexpression of MRP1 did not alter this result.
a,
trypsin-stimulated INa versus basal INa (p  0.001);
b, basal INa of ENaC  Mtrp or ENaC  Mtrp  MRP1 versus
basal INa of ENaC alone (p  0.01). Analysis of variance with Tukey’s test was performed (A and C, n  21–22
oocytes combined from five batches).
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in matriptase-expressing oocytes, but these currents could be
robustly stimulated by trypsin. These results were paralleled by
changes in the fragmentation patterns of - and -ENaCs in
lysates from oocytes coexpressing matriptase alone or mat-
riptase with CFTR (Fig. 2B). Matriptase alone strongly con-
verted full-length - and -ENaCs to smaller fragments that
have been shown to arise from cleavages at or near the two furin
cleavage sites in -ENaC and the single furin site and a polyba-
sic RKRK tract in -ENaC (17, 23). Coexpressed CFTR clearly
limited these cleavages (Fig. 2B), andwe showed in other exper-
iments that this inhibition of ENaC
proteolysis was dependent on the
amount of CFTR expressed (supple-
mental Fig. 2). As a control, we
coexpressed MRP1, an ABC pro-
tein similar in size and membrane
topography to CFTR (35), and
observed no effect on stimulation
of INa or -ENaC cleavage by
matriptase (Fig. 2, B and C).
F508 CFTR Does Not Affect Pro-
teolytic Cleavage of ENaC—The CF
mutation F508 CFTR causes mis-
folding and retention of the protein
at the ER in its core-glycosylated
immature form and subsequent ER-
associated degradation (3, 36). A
small number ofF508CFTR chan-
nels may escape to the cell surface
but show reduced chloride channel
function. When coexpressed with
ENaC subunits and matriptase,
F508 CFTR, which appeared as an
immature protein lacking complex
oligosaccharide chains, did not
diminish proteolytic cleavage of
either the ENaC - or -subunit (Fig. 3A). Unlike the block of
matriptase-induced stimulation of INa and restoration of tryp-
sin sensitivity by wild-type CFTR, coexpressed F508 had no
effect on matriptase-stimulated INa (Fig. 3B).
CFTR and ENaC Associate in Primary HAE Cultures—We
followed up on these heterologous expression experiments by
asking whether the extent of ENaC proteolysis differed in nor-
mal and CF airway epithelia. To analyze endogenous ENaC in
primary HAE cultures, we developed mAbs detecting epitopes
in the N- or C-terminal tails of individual ENaC subunits. The
mouse anti--ENaCmonoclonal antibody (mAb UNC1 19.2.1;
supplemental Fig. 1) allowed for particularly robust detection of
ENaC endogenously expressed in primary HAE cultures, and
weused this antibody to test for association of ENaCwithCFTR
by co-immunoprecipitation. As shown in Fig. 4A, the presence
of-ENaC in proteins immunoprecipitated by anti-CFTR anti-
body was readily detected.
CFTR Impedes Proteolysis of ENaC in Primary HAECultures—
We employed mAb UNC1 19.2.1 (supplemental Fig. 1) to
examine the effect of CFTR on proteolytic processing of
-ENaC natively expressed in HAE cultures. First, we prepared
lysates of well differentiated airway epithelial cells cultured
from three normal individuals and visualized the banding pat-
tern of -ENaC.mAbUNC1 19.2.1mainly stained an83-kDa
band consistent with full-length -ENaC. A less intense, more
rapidly migrating band of 65 kDa was also detected. Next, we
generated lysates from CF HAE cultures of three patients that
were homozygous for F508 CFTR. Western blots with anti-
CFTRmAb596 confirmed the absence ofmatureCFTRand the
expression of core-glycosylated immature mutant protein. In
the absence of functional CFTR,-ENaC appearedmore prom-
inently in the 65-kDa band. Similar fragmentation patterns
FIGURE 3. F508 CFTR does not diminish proteolysis of ENaC. A, Xenopus oocytes were injected with all
three ENaC subunits, whereby either the - or -subunit was tagged at the N and C termini with HA and V5
epitopes, respectively. CFTR or F508 CFTR was coexpressed with ENaC and matriptase (Mtrp). Oocyte lysates
were analyzed by Western blotting as described for Fig. 3. B, wild-type CFTR but not F508 CFTR interferes with
stimulation of ENaC by matriptase. INa of (ENaC  Mtrp)-expressing oocytes was not further stimulated by a
5-min exposure to trypsin (2 g/ml). Coexpression of wild-type CFTR but not F508 CFTR significantly
decreased basal INa, and the reduced current was partially recovered by trypsin. Data were combined from
three batches of oocytes (n  16 –17). a, basal INa of ENaC  Mtrp  CFTR versus basal INa of ENaC  Mtrp or
ENaC  Mtrp  F508 CFTR (p  0.01); b, trypsin-stimulated INa versus basal INa (p  0.05). Analysis of variance
with Tukey’s test was applied.
FIGURE 4. Endogenous CFTR and ENaC co-immunoprecipitate, and CFTR
impedes proteolysis of ENaC in primary HAE cultures. A, -ENaC co-immu-
noprecipitates with CFTR in primary airway cells (HAE). CFTR was immunopre-
cipitated (IP) with rabbit anti-CFTR Ab and pulled down with protein A-agar-
ose beads, and associated -ENaC was detected with mAb UNC1 19.2.1. CFTR
was visualized with mAb 596. Control lysates were treated identically but did
not contain anti-CFTR Ab. 2% of immunoprecipitation inputs were loaded.
B, ENaC is less cleaved in normal (NL) primary HAE cultures than in CF cultures
(F508/F508). Primary human HAE cells were grown on an air-liquid inter-
face until well polarized, and lysates were analyzed by Western blotting with
anti--ENaC mAb UNC1 19.2.1. Three different cultures with cells derived
from three different normal or CF individuals were analyzed. CFTR was visu-
alized with mAb 596 after immunoprecipitation with rabbit polyclonal Ab.
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were seen when -ENaC was detected in mouse lung tissue
homogenate (37) and when -ENaC was coexpressed with
TMPRSS4 in Xenopus oocytes (23). Although we were not suc-
cessful in developing antibodies to assess endogenous -ENaC
proteolysis in airways, both - and -ENaCs were protected
similarly by CFTR in oocytes (Figs. 2 and 3 and supplemen-
tal Fig. 2). Thus, our results suggest that CFTR in airway epi-
thelia impedes the proteolytic processing of ENaC, which has
been strongly associatedwith increasedENaCopenprobability.
DISCUSSION
We found CFTR and ENaC coexpressed in oocytes to co-
immunoprecipitate, similar to earlier reports (7, 20, 21).
Importantly, the pool of -ENaC found in the proteins immu-
noprecipitated by anti-CFTR antibody showed fewer signs of
cleavage by endogenous oocyte proteases, and functional assays
clearly indicated that ENaC coexpressed with CFTR was pro-
tected from proteolytic activation. This finding was extended
by studies revealing that CFTR coexpression prevented full
cleavage and activation of ENaC by the coexpressed surface-
acting protease matriptase. This protection against cleavage
and stimulation by matriptase was not shared by coexpression
of F508 CFTR or MRP1, an ABC transport protein related to
CFTR (Figs. 2 and 3). The concordance of these functional and
biochemical data in oocytes allays concerns that CFTR-medi-
ated inhibition of ENaC in these experiments is an artifact of
the two-electrode voltage clamp technique (14).
We were able to bridge our observations in the oocyte
expression system to the regulation of ENaC in human tissue by
demonstrating that CFTR and ENaC co-immunoprecipitate in
normal humanprimary airway epithelia (Fig. 4). The expression
of mature CFTR in normal airway epithelia has long been
inferred to check the rate of Na absorptionmediated by ENaC
(38). Importantly, we found ENaC to be more fragmented in
airway epithelial cells cultured from CF patients lacking appre-
ciable CFTR in their apical membranes. These data provide
mechanistic insights into published reports of protease-medi-
ated regulation of ENaC in airway epithelial cells. Selective
knockdown of prostasin has firmly implicated net proteolytic
activity on the respiratory surface in the stimulation of ENaC
(39, 40). In addition, Myerburg et al. (41) recently showed that
the content of soluble cognate prostasin inhibitors in ASL is
important in determining ENaC activity in airways. Tarran and
co-workers (42) identified one such soluble mediator as
SPLUNC1 (short palate, lung, and nasal epithelial clone 1),
which impairs proteolytic stimulation undergone by ENaC.
Collectively, these studies established that signals reporting
ASL volume, including protease inhibitor concentration, can
slow Na absorption by preventing proteolytic stimulation of
ENaC and thereby achieve homeostatic control of ASL depth.
Tarran et al. (12) reported several years ago thatNa absorp-
tion of CF airway epithelial cultures is elevated and not further
stimulated by exogenous trypsin, whereas in normal cells under
the same conditions, Na absorption is lower but can be stim-
ulated by trypsin. Thus, in normal cells, ENaC is partially pro-
tected from endogenous proteolytic stimulation (12). In con-
trast, in CF cells, the same soluble signals that limit ENaC
proteolysis and stimulation in normal cells, such as protease
inhibitors and SPLUNC1, are present but insufficient to pre-
vent full proteolytic stimulation of ENaC (12). Tarran et al.
restored regulation of ENaC and ASL depth to CF cultures by
experimentally increasing protease inhibition with exogenous
aprotinin. Our finding that ENaC ismore extensively cleaved in
CF airway epithelial cells is entirely consistent with these func-
tional studies and with observations by Chinet et al. (43) of
greater open probability of Na-permeable channels in CF air-
way cells. We propose that the presence of CFTR in normal
cells, through protection against ENaC proteolysis, is required
in addition to soluble protease inhibitors for normal regulation
of ENaC in airway epithelia.
Previous studies demonstrating CFTR-ENaC association did
not definitively explain how proximity of the two ion channels
led to restraint of ENaC function (7, 20, 21). Our work identi-
fies, for the first time, CFTR-mediated inhibition of ENaC pro-
teolysis as a mechanism for negative regulation of ENaC by
CFTR that is seen in airways. Moreover, bidirectional CFTR-
ENaCco-immunoprecipitation and the ability ofCFTR to com-
promise bimolecular interactions between proteases and the
large extracellular domains of ENaC imply an extent of CFTR-
ENaC interaction that could affect ENaC activity in additional
ways. For example, CFTR physically situated near ENaC could
impact signaling pathways that control the trafficking and sur-
face expression of ENaC (13). Other processes or conditions
important for ENaC activity could be influenced by the effects
of CFTR on the pH near the apical surface (44, 45) or intracel-
lular ion content (46, 47). Importantly, our results provide a
concrete mechanism of CFTR negative regulation of ENaC in
airway epithelia while leaving open the possibility that other
modes of ENaC regulation are utilized in epithelia with differ-
ent salt and water physiology.
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